Previous 10 | Next 10 |
2024-02-13 12:36:00 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals: Gene Therapy Pioneer On A High Rocket Pharmaceuticals: Promising, But Not A Rocket At This Valuation Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals Historical earning...
New Prescription Drug User Fee Act (PDUFA) date of June 30, 2024 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the U.S. ...
2024-02-12 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-21 02:50:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2023, Baron Health Care Fund® (the Fund) advanc...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 42 n...
2023-12-24 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to i...
2023-12-06 06:45:53 ET Summary Rocket has an accepted BLA filing with a PDUFA date of 3/31/2023. The stock has experienced volatile trading patterns, with no clear explanation for these fluctuations. Rocket's lead therapeutic candidate, KRESLADI, has the potential for a signif...
2023-12-05 22:38:44 ET Summary Rocket Pharmaceuticals is a biotech company that develops gene therapies for rare and life-threatening genetic disorders. The company's pipeline includes programs for severe LAD-I and Danon disease, with potential sales of $1.3 billion by 2030. R...
2023-11-06 17:49:25 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead? Rocket Pharma gains as Cantor sees $65 price targ...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...
Long-term KRESLADI TM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients with severe LAD-I Previously disclosed results from the global R...